Evidence map›Paper›PMID 41265435›Full record

ArticleCell2026

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.

Alexander C Lewis, Emily Gruber, Rheana Franich, Jessica Armstrong, Madison J Kelly, Carlos M Opazo, Yau C Low, Léa Flippe, Kevin Wijanarko, Caitlin L Rowe and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Regulated cell death programs shaping cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  12. Article
  13. Localized heme sensing through a ternary molecular glue.bioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Alexander C LewisPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Emily GruberPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Rheana FranichPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Jessica ArmstrongPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Madison J KellyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Carlos M OpazoFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
Yau C LowMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia.
Léa FlippeMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Kevin WijanarkoMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Caitlin L RoweDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Celeste H MawalFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
Alexandra BirrellPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Joan SoPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Srimayee VaidyanathanPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Keziah TingPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Liana N SemcesenDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC 3010, Australia.
Karena LastDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC 3010, Australia.
Ching-Seng AngBio21 Institute, University of Melbourne, Parkville, VIC 3052, Australia.
Giovanna PomilioWalter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
Fiona C BrownWalter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
Andrew H WeiPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Royal Melbourne Hospital, Melbourne, VIC 3052, Australia.
Jason A PowellCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia; Adelaide Medical School, Faculty of Health Sciences, University of Adelaide, Adelaide, SA 5000, Australia.
Elizabeth S NgMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Ann E FrazierMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia.
Kate McArthurDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Najoua LalaouiPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
David A StroudMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC 3010, Australia; Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia.
Kristin K BrownPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC 3010, Australia.
Ricky W JohnstonePeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia.
Lev M KatsPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia. Electronic address: lev.kats@petermac.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ubiquitous metabolite heme has diverse enzymatic and signaling functions in most mammalian cells. Through integrated analyses of mouse models, human cell lines, and primary patient samples, we identify de novo heme biosynthesis as a selective dependency in acute myeloid leukemia (AML). The dependency is underpinned by a propensity of AML cells, and especially leukemic stem cells (LSCs), to downregulate heme biosynthesis enzymes (HBEs), which promotes their self-renewal. Inhibition of HBEs causes the collapse of mitochondrial Complex IV and dysregulates the copper-chaperone system, inducing cuproptosis, a form of programmed cell death brought about by the oligomerization of lipoylated proteins by copper. Moreover, we identify pathways that are synthetic lethal with heme biosynthesis, including glycolysis, which can be leveraged for combination strategies. Altogether, our work uncovers a heme rheostat that is connected to gene expression and drug sensitivity in AML and implicates HBE inhibition as a trigger of cuproptosis.

Indexed as

CopperHemeLeukemia, Myeloid, AcuteAnimalsApoptosisCell Line, TumorHumansMiceMitochondriaNeoplastic Stem CellsCopperHemeacute myeloid leukemiacuproptosisheme biosynthesismetabolic vulnerabilitymetabolismmitochondrial Complex IV

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.